Drug Therapy in Adult Congenital Heart Disease Heart Failure

  • Pieter De Meester
  • Werner BudtsEmail author
Part of the Congenital Heart Disease in Adolescents and Adults book series (CHDAA)


As in acquired heart failure (HF), drug therapy is a major component of HF treatment in ACHD. However its precise role and the optimum treatment strategies are controversial in this evidence-sparse field. This chapter offers a structured and systematic approach to considering the best pharmaceutical intervention for the various types of ACHD-related HF. The current literature is reviewed and suggestions made about how best to apply this to clinical practice. The importance of expert opinion and consolidated experience in treating complex ACHD patients with HF cannot be overemphasised.


Beta-blockers Renin-angiotensin-aldosterone system inhibitors Ivabradine Neprilysin inhibitor 


  1. 1.
    Tutarel O, Kempny A, Alonso-Gonzalez R, Jabbour R, Li W, Uebing A, Dimopoulos K, Swan L, Gatzoulis MA, Diller GP. Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. Eur Heart J. 2014;35:725–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk AP, Vliegen HW, Grobbee DE, Mulder BJ. Mortality in adult congenital heart disease. Eur Heart J. 2010;31:1220–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Members ATF. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRefGoogle Scholar
  4. 4.
    McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Committees P-HIa. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, Coats AJ, Anker SD, Gatzoulis MA. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002;106:92–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Budts W, Roos-Hesselink J, Rädle-Hurst T, Eicken A, McDonagh TA, Lambrinou E, Crespo-Leiro MG, Walker F, Frogoudaki AA. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. Eur Heart J. 2016;37:1419–27.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ohuchi H, Takasugi H, Ohashi H, Okada Y, Yamada O, Ono Y, Yagihara T, Echigo S. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation. 2003;108:2368–76.CrossRefPubMedGoogle Scholar
  8. 8.
    Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, Everitt MD, Gatzoulis M, Harris L, Hsu DT, Kuvin JT, Law Y, Martin CM, Murphy AM, Ross HJ, Singh G, Spray TL, American Heart Association Council on Clinical Cardiology CuoFGaTB, and Council on Cardiovascular Radiology and Imaging. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2016;133:770–801.PubMedGoogle Scholar
  9. 9.
    Moltzer E, Mattace Raso FU, Karamermer Y, Boersma E, Webb GD, Simoons ML, Danser AH, van den Meiracker AH, Roos-Hesselink JW. Comparison of Candesartan versus Metoprolol for treatment of systemic hypertension after repaired aortic coarctation. Am J Cardiol. 2010;105:217–22.CrossRefPubMedGoogle Scholar
  10. 10.
    Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527–34.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cuypers JA, Eindhoven JA, Slager MA, Opić P, Utens EM, Helbing WA, Witsenburg M, van den Bosch AE, Ouhlous M, van Domburg RT, Rizopoulos D, Meijboom FJ, Bogers AJ, Roos-Hesselink JW. The natural and unnatural history of the Mustard procedure: long-term outcome up to 40 years. Eur Heart J. 2014;35:1666–74.CrossRefPubMedGoogle Scholar
  12. 12.
    Dobson R, Danton M, Nicola W, Hamish W. The natural and unnatural history of the systemic right ventricle in adult survivors. J Thorac Cardiovasc Surg. 2013;145:1493–501. discussion 1501–3CrossRefPubMedGoogle Scholar
  13. 13.
    Winter MM, Bouma BJ, van Dijk AP, Groenink M, Nieuwkerk PT, van der Plas MN, Sieswerda GT, Konings TC, Mulder BJ. Relation of physical activity, cardiac function, exercise capacity, and quality of life in patients with a systemic right ventricle. Am J Cardiol. 2008;102:1258–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Winter MM, Scherptong RW, Kumar S, Bouma BJ, Tulevski II, Tops LF, Roest AA, Vliegen HW, de Roos A, Groenink M, Mulder BJ. Ventricular response to stress predicts outcome in adult patients with a systemic right ventricle. Am Heart J. 2010;160:870–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Book WM, Hott BJ, McConnell M. B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am J Cardiol. 2005;95:545–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Koch AM, Zink S, Singer H. B-type natriuretic peptide in patients with systemic right ventricle. Cardiology. 2008;110:1–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Chow PC, Cheung EW, Chong CY, Lun KS, Yung TC, Wong KT, Chau AK, Cheung YF. Brain natriuretic peptide as a biomarker of systemic right ventricular function in patients with transposition of great arteries after atrial switch operation. Int J Cardiol. 2008;127:192–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Dore A, Houde C, Chan KL, Ducharme A, Khairy P, Juneau M, Marcotte F, Mercier LA. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation. 2005;112:2411–6.CrossRefPubMedGoogle Scholar
  19. 19.
    van der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, van Dijk AP, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJ. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013;127:322–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Doughan AR, McConnell ME, Book WM. Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol. 2007;99:704–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Robinson B, Heise CT, Moore JW, Anella J, Sokoloski M, Eshaghpour E. Afterload reduction therapy in patients following intraatrial baffle operation for transposition of the great arteries. Pediatr Cardiol. 2002;23:618–23.CrossRefPubMedGoogle Scholar
  22. 22.
    Therrien J, Provost Y, Harrison J, Connelly M, Kaemmerer H, Webb GD. Effect of angiotensin receptor blockade on systemic right ventricular function and size: a small, randomized, placebo-controlled study. Int J Cardiol. 2008;129:187–92.CrossRefPubMedGoogle Scholar
  23. 23.
    Hechter SJ, Fredriksen PM, Liu P, Veldtman G, Merchant N, Freeman M, Therrien J, Benson L, Siu S, Webb G. Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol. 2001;87:660–3. A11CrossRefPubMedGoogle Scholar
  24. 24.
    Lester SJ, McElhinney DB, Viloria E, Reddy GP, Ryan E, Tworetzky W, Schiller NB, Foster E. Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J Cardiol. 2001;88:1314–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Giardini A, Lovato L, Donti A, Formigari R, Gargiulo G, Picchio FM, Fattori R. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol. 2007;114:241–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Josephson CB, Howlett JG, Jackson SD, Finley J, Kells CM. A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of beta-blockade. Can J Cardiol. 2006;22:769–72.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Dos L, Pujadas S, Estruch M, Mas A, Ferreira-González I, Pijuan A, Serra R, Ordóñez-Llanos J, Subirana M, Pons-Lladó G, Marsal JR, García-Dorado D, Casaldàliga J. Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study. Int J Cardiol. 2013;168:5167–73.CrossRefPubMedGoogle Scholar
  28. 28.
    Tutarel O, Meyer GP, Bertram H, Wessel A, Schieffer B, Westhoff-Bleck M. Safety and efficiency of chronic ACE inhibition in symptomatic heart failure patients with a systemic right ventricle. Int J Cardiol. 2012;154:14–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Oosterhof T, van Straten A, Vliegen HW, Meijboom FJ, van Dijk AP, Spijkerboer AM, Bouma BJ, Zwinderman AH, Hazekamp MG, de Roos A, Mulder BJ. Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. Circulation. 2007;116:545–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Baumgartner H, Bonhoeffer P, De Groot NMS, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJM, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E, Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of C, Association for European Paediatric C and Guidelines ESCCfP. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31:2915–57.CrossRefGoogle Scholar
  31. 31.
    Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Halperin JL, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Page RL, Riegel B, Tarkington LG, Yancy CW, American College of C, American Heart Association Task Force on Practice G, American Society of E, Heart Rhythm S, International Society for Adult Congenital Heart D, Society for Cardiovascular Angiography and I and Society of Thoracic S. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in collaboration with the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:e143–263.CrossRefGoogle Scholar
  32. 32.
    Helbing WA, Niezen RA, Le Cessie S, van der Geest RJ, Ottenkamp J, de Roos A. Right ventricular diastolic function in children with pulmonary regurgitation after repair of tetralogy of Fallot: volumetric evaluation by magnetic resonance velocity mapping. J Am Coll Cardiol. 1996;28:1827–35.CrossRefPubMedGoogle Scholar
  33. 33.
    Babu-Narayan SV, Uebing A, Davlouros PA, Kemp M, Davidson S, Dimopoulos K, Bayne S, Pennell DJ, Gibson DG, Flather M, Kilner PJ, Li W, Gatzoulis MA. Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot). Int J Cardiol. 2012;154:299–305.CrossRefPubMedGoogle Scholar
  34. 34.
    Norozi K, Bahlmann J, Raab B, Alpers V, Arnhold JO, Kuehne T, Klimes K, Zoege M, Geyer S, Wessel A, Buchhorn R. A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot. Cardiol Young. 2007;17:372–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, Aboyans V, Vaz Carneiro A, Achenbach S, Agewall S, Allanore Y, Asteggiano R, Paolo Badano L, Albert Barberà J, Bouvaist H, Bueno H, Byrne RA, Carerj S, Castro G, Erol Ç, Falk V, Funck-Brentano C, Gorenflo M, Granton J, Iung B, Kiely DG, Kirchhof P, Kjellstrom B, Landmesser U, Lekakis J, Lionis C, Lip GY, Orfanos SE, Park MH, Piepoli MF, Ponikowski P, Revel MP, Rigau D, Rosenkranz S, Völler H, Luis Zamorano J. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.CrossRefGoogle Scholar
  36. 36.
    Mahle WT, Wang A, Quyyumi AA, McConnell ME, Book WM. Impact of spironolactone on endothelial function in patients with single ventricle heart. Congenit Heart Dis. 2009;4:12–6.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ringel RE, Peddy SB. Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol. 2003;91:1031–2. A9CrossRefPubMedGoogle Scholar
  38. 38.
    Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008;29:1681–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Van De Bruaene A, La Gerche A, Claessen G, De Meester P, Devroe S, Gillijns H, Bogaert J, Claus P, Heidbuchel H, Gewillig M, Budts W. Sildenafil improves exercise hemodynamics in Fontan patients. Circ Cardiovasc Imaging. 2014;7:265–73.CrossRefGoogle Scholar
  40. 40.
    Goldberg DJ, French B, Szwast AL, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol. 2012;33:689–96.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Shabanian R, Shahbaznejad L, Razaghian A, Kiani A, Rahimzadeh M, Seifirad S, Kocharian A, Gilani JS, Navabi MA. Sildenafil and ventriculo-arterial coupling in Fontan-palliated patients: a noninvasive echocardiographic assessment. Pediatr Cardiol. 2013;34:129–34.CrossRefPubMedGoogle Scholar
  42. 42.
    Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, Gewillig M, Mertens L. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young. 2009;19:331–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Schuuring MJ, Vis JC, van Dijk AP, van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, de Bruin-Bon RH, Mulder BJ, Bouma BJ. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013;15:690–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Anderson PA, Breitbart RE, McCrindle BW, Sleeper LA, Atz AM, Hsu DT, Lu M, Margossian R, Williams RV. The Fontan patient: inconsistencies in medication therapy across seven pediatric heart network centers. Pediatr Cardiol. 2010;31:1219–28.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Hsu DT, Zak V, Mahony L, Sleeper LA, Atz AM, Levine JC, Barker PC, Ravishankar C, McCrindle BW, Williams RV, Altmann K, Ghanayem NS, Margossian R, Chung WK, Border WL, Pearson GD, Stylianou MP, Mital S, Investigators PHN. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation. 2010;122:333–40.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Vonder Muhll I, Liu P, Webb G. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease. Int J Cardiol. 2004;97(Suppl 1):25–33.CrossRefPubMedGoogle Scholar
  47. 47.
    Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation. 1997;96:1507–12.CrossRefPubMedGoogle Scholar
  48. 48.
    Ishibashi N, Park IS, Waragai T, Yoshikawa T, Murakami Y, Mori K, Mimori S, Ando M, Takahashi Y, Doi S, Mizutani S, Nakanishi T. Effect of carvedilol on heart failure in patients with a functionally univentricular heart. Circ J. 2011;75:1394–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Lee KJ, Yoo SJ, Holtby H, Grant B, Mroczek D, Wong D, Grosse-Wortmann L, Benson LN, Chaturvedi RR. Acute effects of the ACE inhibitor enalaprilat on the pulmonary, cerebral and systemic blood flow and resistance after the bidirectional cavopulmonary connection. Heart. 2011;97:1343–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, Investigators C-H. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657–68.CrossRefPubMedGoogle Scholar
  51. 51.
    Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R, Vachiéry JL, Paelinck B, Morissens M, Budts W. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J. 2011;32:2790–9.CrossRefGoogle Scholar
  52. 52.
    Mascitelli L, Pezzetta F, Goldstein MR. Reduced body iron stores and atherosclerosis in patients with cyanotic congenital heart disease. Int J Cardiol. 2011;146:117.CrossRefPubMedGoogle Scholar
  53. 53.
    Tay EL, Peset A, Papaphylactou M, Inuzuka R, Alonso-Gonzalez R, Giannakoulas G, Tzifa A, Goletto S, Broberg C, Dimopoulos K, Gatzoulis MA. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol. 2011;151:307–12.CrossRefPubMedGoogle Scholar
  54. 54.
    Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY, Group PCS. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298:1171–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Bouallal R, Godart F, Francart C, Richard A, Foucher-Hossein C, Lions C. Interest of β-blockers in patients with right ventricular systemic dysfunction. Cardiol Young. 2010;20:615–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Khairy P, Harris L, Landzberg MJ, Fernandes SM, Barlow A, Mercier LA, Viswanathan S, Chetaille P, Gordon E, Dore A, Cecchin F. Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol. 2008;1:250–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Congenital and Structural Cardiology, Department of Cardiovascular SciencesUniversity Hospitals Leuven, Catholic University LeuvenLeuvenBelgium

Personalised recommendations